Skip to main content
main-content

Diabetes complications and comorbidities: Cardiovascular disease

medwireNews top story

Stricter BP thresholds may be needed in type 1 diabetes

Testing blood pressure (symbolic image with models)

Findings from an observational cohort study suggest that a blood pressure target of 120/80 mmHg may be needed for effective prevention of coronary artery disease in people with type 1 diabetes.

medwireNews top story

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Kidneys

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

The REWIND trial

Cardiovascular disease (illustration)
Expert opinion editorial

The CAROLINA trial: Make or break for sulfonylureas?

Sulfonylurea pill

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas. 

Get more on: Sulfonylureas | DPP-4 inhibitors | Other diabetes medications

medwireNews feature

Young-onset type 2 diabetes: A different process?

Overweight woman at doctor's (symbolic image with models)

Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.

medwireNews top story

Any pregnancy dysglycemia may raise CVD risk

Pregnant woman_doctor with clipboard

The association between poor glycemic control during pregnancy and subsequent risk for cardiovascular disease extends to women without gestational diabetes, study findings suggest.

medwireNews top story

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Heartbeat

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

Patient case study

Cardiovascular risk reduction in type 2 diabetes

Heart and stethoscope

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this case study [read more].

Get more on: Cardiovascular disease | SGLT2 inhibitors | GLP-1 receptor agonists

medwireNews editor's pick

Gap in cardiovascular risk not closing for people with type 2 diabetes

Heartbeat

The incidence of coronary heart disease has declined in recent years but people with type 2 diabetes continue to have a significantly greater risk than those without, Scottish data show.

medwireNews editor's pick

High mental illness burden in young-onset type 2 diabetes

Hospital

Over a third of time spent in hospital before the age of 40 years by patients who develop type 2 diabetes by this age is due to mental illness, report researchers.

medwireNews

07-18-2019 | Heart failure | News

Diabetes-associated heart failure risk greatest in women

Diabetes is a stronger risk factor for heart failure among women compared with men, indicate the results of a large systematic review and meta-analysis.

07-04-2019 | Heart failure | News

Sex difference in HF diabetes impact extended to Asians

Registry data support a larger impact of diabetes on hospitalization and mortality risk in women than men with heart failure.

06-26-2019 | Heart failure | News

Post HF diabetes development increases mortality risk

People who develop diabetes after hospitalization for heart failure have a significantly greater risk for death than people who do not have or develop diabetes, study findings indicate.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-28-2018 | Diabetic cardiomyopathy | Article

Cardiovascular risk reduction over time in patients with diabetes or pre-diabetes undergoing bariatric surgery: data from a single-center retrospective observational study

Rubio-Almanza M, Cámara-Gómez R, Hervás-Marín D et al. BMC Endocr Disord 2018; 18: 90. doi: 10.1186/s12902-018-0317-4

11-21-2018 | Cardiovascular disorders | Review | Article

Unrecognised cardiovascular disease in type 2 diabetes: Is it time to act earlier?

Schernthaner G et al. Cardiovasc Diabetol 2018; 17: 145. doi: 10.1186/s12933-018-0788-7

11-10-2018 | Retinopathy | Article

Diabetic retinopathy grade as a predictive marker of severity of cardiovascular disease and mortality: DIVERSE Study Group

Shah K et al. Int J Diabetes Dev Ctries 2018. doi: 10.1007/s13410-018-0699-x

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits